semaglutide producers India's generic surge | Opinion GLP-1s | AgelessRx
Description
Front Oncol 12
Daewoong Pharmaceutical is poised to enter this market with its innovative microneedle obesity treatment by 2028, aiming to revolutionize the sector by addressing the limitations of current therapies, especially in improving treatment adherencea significant challenge highlighted by Eli Lilly's CSO, Dr
However, remaining fat cells throughout the body can still expand with weight gain
Do not leave it on the counter
Daewoong Pharmaceutical is set to initiate Phase 1 clinical trials early next year, with the goal of commercializing the product by 2028
